17,261 trials
Depressive Disorder · Depression · Depression, Postpartum
Primary: Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Through Treatment — -8.0; -5.7; -0.8; -2.6 score on a scale
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Peanut Allergy
Primary: Percentage of Participants Experiencing Treatment-emergent Adverse Events During the 2-stage Study Sequence (Safety) — 60 percentage of participants
Myocardial Infarction · Inflammation
Primary: Area Under the Curve (AUC) for C-reactive Protein (CRP) — 133 mg*day/L
Ulcerative Colitis
Primary: Change From Baseline in Total MCS at Week 6 — -2.6; -2.6 units on a scale — p=0.981
Amoebic Dysentery · Giardiasis
Primary: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose…
Breast Cancer
Primary: Number of Evaluable Patients With Dose Limiting Toxicity Events in Phase 1 — 1; 0; 4; 2 Participants
Presbyopia
Primary: Number of Subjects With ≥ 3 Lines Gain in Near Best Distance Corrected Visual Acuity (BDCVA) (at 40 cm) — 10; 12; 10 Participants — p=0.8445
Hidradenitis Suppurativa · Acne Inversa
Primary: Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 — -2.5; -5.2; -6.9; -6.3 abscesses and inflammatory nodules — p=0.0277
COVID-19
Primary: Modified COVID Ordinal Outcomes Scale: Study Day 15 (Group 2 and Placebo Control Group) — 0; 0; 1; 0 Participants
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure at Week 2 — 19.05; 18.92; 18.28; 17.86 mmHg
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) · Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) · Cohort 3a and 3b: Chondrosarcoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 2; 0; 1 Participants
Metastatic Non-small Cell Lung Cancer · Metastatic Triple-negative Breast Cancer
Primary: Objective Response Rate — 4; 7; 13; 32 Participants
Meibomian Gland Dysfunction (MGD) · Contact Lens Discomfort (CLD)
Primary: Primary Efficacy for MGD: Change From Baseline to Month 4 in Meibum Gland Secretion Score (MGS). — 12.1; 16 Units on the Meibomian Gland Score scale
Hodgkin's Lymphoma · Lymphoid Leukemia · Lymphoma
Primary: The Number of Patients With Relapse-free/Donor Lymphocyte Infusion(DLI)-Free Survival Rates Between Patients Randomized to MMF-30 (Control Cohort) and MMF-15…